AI assistant
Sending…
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2019
Jul 17, 2019
30849_dirs_2019-07-17_6926ed87-3b4b-4953-aa54-65dd27e77e36.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2019-07-16
Reporting Person: Gottesdiener Keith Michael (Director, CEO and President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-07-16 | Common Stock | M | 7500 | $4.59 | Acquired | 513842 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-07-16 | Employee Stock Option (Right to Buy) | $4.59 | M | 7500 | Disposed | 2025-11-16 | Common Stock (7500) | Direct |
Footnotes
F1: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015.
More from RHYTHM PHARMACEUTICALS, INC.
Proxy Solicitation & Information Statement
2026
May 29
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 3
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 20
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 3